Doxorubicin Induces Fas-Mediated Apoptosis in Human Thyroid Carcinoma Cells

Thyroid

Volumn 14, Issue 4, 2004, Pages 263-270

  Massart, C ^a   Barbet, R ^a   Genetet, N ^a   Gibassier, J ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; DNA; DOXORUBICIN; FAS ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ANNEXIN A5; ANTIGENS, CD95; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; THYROID NEOPLASMS;

EID: 2342655178     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072504323030915     Document Type: Article

References (25)

1. Robbins J, Merino MJ, Boice JD, Ron E, Ain KB, Alexander HR, Norton JA 1991 Thyroid cancer: A lethal endocrine neoplasm. Ann Intern Med 115:133-147.
2. Schlumberger M 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
3. Solomon BL, Wartofsky L, Burman KD 1996 Current trends in the management of well differentiated papillary carcinoma. J Clin Endocrinol Metab 81:333-339.
4. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D 1991 Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67:564-566.
5. Fischer DE 1994 Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542.
6. Lumachi F, Basso S 2002 Apoptosis: Life through planned cellular death regulating mechanisms, control systems, and relations with thyroid diseases. Thyroid 12:27-34.
7. Nagata S, Golstein P 1995 The Fas death factor. Science 267:1449-1456.
8. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT 1997 Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89:783-789.
9. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O 2000 Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 60:2912-2918.
10. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
11. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
12. Massart C, Gibassier J, Raoul ML, Pourquier P, Leclech G, Robert J, Lucas C 1995 Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anticancer Drugs 6:135-146.
13. Yeung SCJ, Xu G, Pan J, Christgen M, Bamiagis A 2000 Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650-656.
14. Muller I, Jenner A, Bruchelt G, Niethammer D, Haliwell B 1997 Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem Biophys Res Commun 230:254-257.
15. Wu XX, Kakehi Y, Mizutani Y, Kamamoto T, Kinoshita H, Isogawa Y, Terachi T, Ogawa O 2002 Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 20:949-954.
16. Willye AH, Morris RG, Smith AL, Dunlop D 1984 Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142:67-77.
17. Negoescu A, Guillermet C, Lorimier P, Brambilla E, Labat-Moleur F 1998 Importance of DNA fragmentation in apoptosis with regard to TUNEL specificity. Biomed Pharmacother 52:252-258.
18. Vitale M, Di Matola T, D'Ascoli F, Salzano S, Bogazzi F, Fenzi G, Martino E, Rossi G 2000 Iodide excess induces apoptosis in thyroid cells through a P53-independent mechanism involving oxidative stress. Endocrinology 141:598-605.
19. Keer JFR, Winterford CM, Harmon BV 1994 Apoptosis: Its significance in cancer and cancer therapy. Cancer 73: 2013-2026.
20. Simon D, Goretzki PE, Reihaus E, Lyons J, Haubruck H, Roher H 1994 Significance of p53 in human thyroid tumors. World J Surg 18:535-540.
21. Arscott PL, Stokes T, Myc A, Giordano TJ, Thompson NW, Baker JR 1999 Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol Metab 84: 4246-4252.
22. Kotchetkov R, Gröschel B, Gmeiner WH, Krivtchik AA, Trump E, Bitoova M, Cinatl J, Kornhuber B, Cinatl J 2000 Antineoplastic activity of a novel multimeric gemcitabine-monophosphate prodrug against cancer cells in vitro. Anticancer Res 20:2915-2922.
23. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH 1989 Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305.
24. McGahon AJ, Costa PA, Daly L, Cotter TG 1998 Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 101:539-547.
25. Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M 1998 Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: Association with Bcl-2 phosphorylation but neither activation of P53 nor G2/M cell cycle arrest. Br J Cancer 77:404-411.